A Web site-based reporting system for monitoring home treatment during oral immunotherapy for XXXX .

@entity1 @entity262 @entity5419
BACKGROUND: Reactions during the home treatment phase of oral immunotherapy (OIT) are not uncommon. An ongoing accurate reporting of home treatment outcomes is crucial for the safety and success of OIT. Previous reports have shown that as few as 20% of @entity1 are truly compliant with paper-based diaries. OBJECTIVE: To develop a @entity262 ( @entity262 ) for monitoring home treatment during OIT for @entity5419 . METHODS: A @entity262 was developed and incorporated a thorough questionnaire querying for pertinent data including the dose(s) consumed, occurrence and details of adverse reactions, treatment(s), and relevant potential exacerbating factors. All @entity1 enrolled in milk, peanut, or egg OIT programs for at least 4 weeks from November 2012 through January 2014 were introduced to @entity262 (n  = 157). Successful reporting through @entity262 was defined by consecutive reporting during the first home treatment phase (24 days) after its introduction. Comparisons were made with a previous group of OIT-treated @entity1 (n  = 100) who reported by E-mail. RESULTS: Successful reporting was achieved by 142 of 157 @entity1 (90.44%) in contrast to a 75% success rate with E-mail (P  = .0009). The odds for successful reporting using @entity262 were 3.1 (95% confidence interval 1.6-6.3) times higher compared with using E-mail. Mild reactions were reported more frequently with @entity262 (P  = .0032). @entity1 reports were constantly available in real time for medical staff review. No complaints regarding @entity262 feasibility were reported. One risk factor for failure to use @entity262 was a @entity1 's prior successful OIT experience without using @entity262 (P  = .012). CONCLUSION: A @entity262 can be a powerful tool for improving OIT safety by achieving a high level of @entity1 cooperation in reporting home treatment results.
